Diarrhoea

• Reduces diarrhea duration by day 2, with only 48% experiencing persistent symptoms versus 80% with placebo

• Produces antimicrobial reuterin compound that directly inhibits E. coli, Salmonella, C. difficile and rotavirus

• Strengthens intestinal barrier by enhancing mucin production and epithelial tight junction integrity

• Clinically proven to reduce diarrhea duration - only 48% experienced persistent diarrhea versus 80% with placebo

• Significantly increases weekly bowel movements while reducing abdominal discomfort, pain, and bloating

• Produces antimicrobial compound reuterin that inhibits E. coli, Salmonella, C. difficile, and rotavirus

• Reduces abdominal pain by 59% and overall IBS symptom severity by 60%

• Spore-forming technology survives stomach acid for targeted small intestine delivery

• Clinically proven to alleviate urgent bowel motions and digestive discomfort